Drug Profile

Sotalol oral solution - Arbor Pharmaceuticals

Alternative Names: AR05; Sotalol hydrochloride oral solution - Arbor Pharmaceuticals; Sotylize

Latest Information Update: 26 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arbor Pharmaceuticals
Class Antihypertensives; Class III antiarrhythmics; Ethanolamines
Mechanism of Action Beta adrenergic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Atrial fibrillation; Atrial flutter; Ventricular arrhythmias

Most Recent Events

23 Oct 2014 Registered for Atrial fibrillation in USA (PO)
23 Oct 2014 Registered for Atrial flutter in USA (PO)
23 Oct 2014 Registered for Ventricular arrhythmias in USA (PO) - First global approval

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com